O Keefe Stevens Advisory Inc. Acquires 991 Shares of Amgen Inc. (NASDAQ:AMGN)

O Keefe Stevens Advisory Inc. boosted its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 2.1% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 48,999 shares of the medical research company's stock after acquiring an additional 991 shares during the quarter. Amgen accounts for approximately 5.0% of O Keefe Stevens Advisory Inc.'s investment portfolio, making the stock its 4th biggest holding. O Keefe Stevens Advisory Inc.'s holdings in Amgen were worth $15,266,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in AMGN. Vanguard Group Inc. increased its stake in shares of Amgen by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 52,721,795 shares of the medical research company's stock worth $13,741,409,000 after purchasing an additional 339,522 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Amgen by 25.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 13,205,604 shares of the medical research company's stock valued at $3,441,909,000 after purchasing an additional 2,672,975 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Amgen by 2.9% during the 4th quarter. Geode Capital Management LLC now owns 12,475,032 shares of the medical research company's stock worth $3,245,881,000 after acquiring an additional 352,143 shares during the last quarter. Capital International Investors lifted its holdings in shares of Amgen by 40.1% during the 4th quarter. Capital International Investors now owns 12,212,065 shares of the medical research company's stock worth $3,182,843,000 after acquiring an additional 3,495,503 shares during the last quarter. Finally, Capital World Investors boosted its position in Amgen by 1,292.0% during the fourth quarter. Capital World Investors now owns 6,495,710 shares of the medical research company's stock valued at $1,693,042,000 after buying an additional 6,029,058 shares during the period. Institutional investors own 76.50% of the company's stock.

Amgen Price Performance

Shares of Amgen stock traded up $3.19 during trading hours on Thursday, reaching $290.20. 906,776 shares of the company's stock were exchanged, compared to its average volume of 2,799,313. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. The business has a fifty day moving average of $282.39 and a two-hundred day moving average of $285.31. The company has a market capitalization of $156.04 billion, a P/E ratio of 38.44, a price-to-earnings-growth ratio of 2.63 and a beta of 0.51.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical research company reported $4.90 EPS for the quarter, beating analysts' consensus estimates of $4.18 by $0.72. The company had revenue of $8.15 billion for the quarter, compared to analysts' expectations of $8.05 billion. Amgen had a net margin of 12.24% and a return on equity of 176.32%. Amgen's revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.96 earnings per share. As a group, research analysts predict that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Morgan Stanley reaffirmed an "equal weight" rating on shares of Amgen in a research note on Friday, May 2nd. UBS Group restated a "neutral" rating and issued a $315.00 price objective (down previously from $319.00) on shares of Amgen in a research report on Friday, May 2nd. Wells Fargo & Company restated an "equal weight" rating on shares of Amgen in a research report on Wednesday, February 5th. Cantor Fitzgerald assumed coverage on shares of Amgen in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $305.00 price target on the stock. Finally, Wall Street Zen upgraded shares of Amgen from a "buy" rating to a "strong-buy" rating in a research report on Sunday, May 18th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $309.22.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.